In this section
RICHMOND, Va., Nov 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that Dr. Geoffrey Allan, President and CEO of Insmed, and Steve Glover, President of Insmed Therapeutic Proteins, will be presenting at the 17th Annual Credit Suisse Healthcare Conference and Rodman & Renshaw 10th Annual Healthcare Conference, respectively.
Dr. Allan will participate on a follow-on biologics-focused panel at the 17th Annual Credit Suisse Healthcare Conference on Wednesday, November 12, 2008 at 3:00 PM MT. The conference will take place in Phoenix, Arizona, from Tuesday, November 11, through Friday, November 14, 2008.
Mr. Glover will be presenting Insmed's corporate presentation on Wednesday, November 12, 2008 at 11:35 AM ET at Rodman & Renshaw's 10th Annual Healthcare Conference in New York City. The conference will take place from Monday, November 10, through Wednesday, November 12, 2008. Insmed's presentation will be webcast live over the Internet and can be accessed directly on http://www.wsw.com/webcast/rrshq14/insm. The webcast will be archived for a period of 90 days.
Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.